¥®¥é¥ó¡¦¥Ð¥ì¡¼¾É¸õ·²¡§Guillain-Barre syndrome |
|---|
|
Àè¹Ô´¶À÷¤È¤·¤Æ¤¤¤¯¤Ä¤«¤Î¥¦¥¤¥ë¥¹¤¬»ØÅ¦¤µ¤ì¤Æ¤¤¤Æ¡¢¥³¥¯¥µ¥Ã¥¡¼¥¦¥¤¥ë¥¹¤ä¥¨¥³¡¼¥¦¥¤¥ë¥¹¤Ê¤É¤¬¸¶°ø»ë¤µ¤ì¤Æ¤¤¤Þ¤¹¡£¤½¤Î¥¦¥¤¥ë¥¹¤ËÂФ¹¤ë¹³ÂΤ¬Ëö¾¿¿À·Ð¤ò¤â¹¶·â¤·¤Æ¤·¤Þ¤¦¤È
¹Í¤¨¤é¤ì¤Æ¤¤¤Þ¤¹¡£
¢£¾É¾õ¡§ ¤³¤Î¥®¥é¥ó¡¦¥Ð¥ì¡¼¾É¸õ·²¤Ï¡¢»Í»è¶ÚÎϤÎÄã²¼¤¬ºÇ¤â½ÅÍפǡ¢²¼»è¤«¤é½ù¡¹¤Ë¾åÂΤ˾ɾõ¤¬¸½¤ì¤Æ¤¤Æ¡¢´éÌÌ¶Ú¤ä¸ÆµÛ¶Ú¤ÎÄã²¼¤¬µ¯¤¤Æ¤¯¤ë¤ÈÓë²¼(¤¨¤ó¤«¡¢¤¨¤ó¤²¡§¿©¤Ùʪ¤ò°ß¤Þ¤Ç°û¤ß²¼¤¹¤³¤È¡Ë¡¢ÒòÓð¡Ê¤½¤·¤ã¤¯¡§¿©¤Ùʪ¤ò³ú¤ßºÕ¤¯¤³¤È¡Ë¡¢¸ÆµÛ¤Ê¤É¤¬º¤Æñ¤Ë¤Ê¤ê¤Þ¤¹¡£¤½¤ì¤Ç¾¯¤Ê¤¯¤È¤â20¿Í¤Ë1¿Í¤Ï¿Í¹©¸ÆµÛ´ï¤¬É¬ÍפˤʤäƤ¤Þ¤¹¡£ ¶ÚÎÏÄã²¼¤Ï4½µ´Ö°ÊÆâ¤Ëƽ¤ò±Û¤¨¤Æ¤½¤Î¸å¥ê¥Ï¥Ó¥ê¥Æ¡¼¥·¥ç¥ó¤ò¹Ô¤¤¤Ä¤Ä½ù¡¹¤Ë²óÉü¤·¤Æ¤¤¤¤Þ¤¹¤¬¡¢È¾Ç¯¤¬²á¤®¤Æ¤â¼«ÎÏÊâ¹Ô½ÐÍè¤Ê¤¤¾ì¹ç¤â¿¤¯¡¢²óÉü¤Ë¿ôǯ¤òÍפ¹¤ë¾ì¹ç¤â¤¢¤ê¤Þ¤¹¡£ ¤Þ¤¿¡¢¤³¤Îɵ¤¤Ë½à¤º¤ë¤â¤Î¤È¤·¤Æ¡¢¥ß¥é¡¼¡¦¥Õ¥£¥Ã¥·¥ã¡¼¾É¸õ·²¤È¸Æ¤Ð¤ì¤Æ¤¤¤ë¤â¤Î¤¬¤¢¤ê¡¢¤³¤ì¤Ï¥«¥ó¥Ô¥í¥Ð¥¯¥¿¡¼¤È¤¤¤¦ºÙ¶Ý¤Ë´¶À÷¤·¤Æµ¯¤³¤¹Éµ¤¤Ç¤¹¡£
¢£¿ÇÃÇ¡¦¼£ÎÅ¡§ ¾åµ¤Î¾É¾õ¤¬¸«¤é¤ì¤¿¤é¡¢¥®¥é¥ó¡¦¥Ð¥ì¡¼¾É¸õ·²¤È¿ÇÃǤ·¤Þ¤¹¡£ °Ê²¼¤ËÌô¤Ë¤è¤ë½èÊýÎã¤ò¼è¤ê¾å¤²¤Þ¤¹¡£ Ìȱ֥°¥í¥Ö¥ê¥óÂçÎÌÀÅÃíÎÅË¡(intravenous immunoglobulin¡§IVIg¡Ë¡¦½èÊýÎã¡¢¤òÊ»ÍѤΤ³¤È¡£ ¡¥³¥Ï¥¯»À¥á¥Á¥ë¥×¥ì¥É¥Ë¥¾¥í¥ó¥Ê¥È¥ê¥¦¥à¡Ê¥½¥ë¡¦¥á¥É¥í¡¼¥ë500¡Ë¡¡1Æü1²ó500mg¡¡5Æü´ÖÅÀÅ©ÀÅ Ãí À¸Íý¿©±ö±Õ200mL¤Ë²Ã¤¨¤Æ¡¢IVIg¤ÎÁ°¤ËÅÀÅ©ÀÅÃí¡ÊÍ×2»þ´Ö¡Ë¡£ ¢¸¥·ì¥Ù¥Ë¥í¥ó-µ¡Ê50mg/mL)¡¡1Æü1²ó0.4g/kg 5Æü´Ö¡¡ÅÀÅ©ÀÅÃí ¥®¥é¥ó¡¦¥Ð¥ì¡¼¾É¸õ·²¡§Guillain-Barre syndrome¡¡¡¡¡¡¼«¸ÊÌȱ֡§autoimmunity¡¡¡¡¡¡Ëö¾¿¿À·Ð ¼À´µ¡§peripheral nerve diseases ÌȱÖÈ¿±þ¡§immune response¡¡¡¡¡¡¾åµ¤Æ»´¶À÷¡§upper respiratory infection(URI)¡¡¡¡¡¡ ¿ȯ¿À·Ðº¬¥Ë¥å¡¼¥í¥Ñ¥Á¡¼¡§polyradiculoneuropathy¡¡¡¡¡¡´éÌ̶ڡ§facial muscles¡¡¡¡¡¡Óë²¼¡§deglutition¡¡¡¡¡¡ÒòÓð¡§mastication¡¡¡¡¡¡ ¥«¥ó¥Ô¥í¥Ð¥¯¥¿¡¼¡§Campylobacter |